跳至主要内容
临床试验/EUCTR2014-002266-71-GB
EUCTR2014-002266-71-GB进行中(未招募)1 期

The role of Qutenza (topical capsaicin 8%) in treating neuropathic pain from arteriovenous fistulae in patients with end stage renal failure - Qutenza for painful fistulae v1.0

HS Greater Glasgow and Clyde0 个研究点目标入组 20 人开始时间: 2019年6月11日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. End stage renal failure on dialysis
  • 2. Chronic neuropathic pain arising from the AVF (defined as pain with symptoms to suggest a neuropathic element occurring most days for at least a month which has not responded to simple analgesia)without underlying cause
  • 3. = 18 years old
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • 1. Failure/ inability to consent
  • 2. Local dermatological conditions/ broken skin/ ulceration/ tissue loss at the site of intended drug application
  • 3. Uncontrolled hypetension (systolic BP >200)
  • 4. Proven recent cardiac event within the past 3 months
  • 5. Hypersensitivity to the active substance or any of the excipients
  • 6. Women who are pregnant or breast feeding
  • 7. Diabetic neuropathy resulting in loss of sensation
  • 8. Current or within 3 months participation in another clinical trial
  • 9. Declines participation
  • 10. Underlying structural or anatomical abnormality within the AVF contributing to the pain

研究者

发起方
HS Greater Glasgow and Clyde

相似试验